-
NICE approves Wegovy™ (semaglutide) for obesity
EuropeanPharmaceuticalReview
February 11, 2022
New draft guidance means thousands of obese Brits could benefit from Novo Nordisk’s Wegovy™ (semaglutide), a drug shown to improve weight loss.
-
New management: Promising drug for people living with obesity
pharmatimes
February 08, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%.
-
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
prnasia
January 18, 2022
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing...
-
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
prnasia
December 29, 2021
EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its wholly owned US subsidiary...
-
Bariatric Surgery Cuts Hepatic Steatosis in Obesity and T2DM
Drugs
November 30, 2021
Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are highly effective for reducing hepatic steatosis in patients with severe obesity and type 2 diabetes, with almost complete clearance of liver fat one year after surgery...
-
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
prnasia
November 08, 2021
Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period.
-
Rates of Obesity, Weight Gain Up for Transmasculine Individuals
drugs
August 26, 2021
Transmasculine individuals have greater rates of obesity and increased weight gain before and during hormone therapy compared with transfeminine individuals, according to a study published online Aug. 16 in the International Journal of Obesity.
-
AstraZeneca and Regeneron to Research, Develop and Commercialize Medicines for Obesity
americanpharmaceuticalreview
July 28, 2021
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
-
FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity
drugs
June 07, 2021
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing.
-
Social & Health Research Center and Quest Diagnostics Team Up to Address Childhood Hunger and Obesity Exacerbated by COVID-19 in Underserved Communities
prnewswire
May 25, 2021
Childhood obesity has disproportionately affected Hispanic and Black communities as a result of negative social determinants of health for years.